Taken together, these findings have important clinical implications, as approximately 5% of metastatic CRPC patients harbor activating PIK3CA alterations in the setting of wild-type PTEN and thus may benefit from p110α-specific inhibition combined with AR targeting therapies, similar to that reported in breast cancer patients in the SOLAR1 Trial. This evidence concerns the gene PTEN and breast cancer.